The biggest barrier to positive clinical outcomes in multiple myeloma is access, explained Robert Rifkin, MD, FACP, medical director, biosimilars and associate chair, hematology research, McKesson Specialty Health.
The biggest barrier to positive clinical outcomes in multiple myeloma is access, explained Robert Rifkin, MD, FACP, medical director, biosimilars and associate chair, hematology research, McKesson Specialty Health.
TranscriptWhat are the biggest barriers to positive clinical outcomes in multiple myeloma?
I think the barriers are interesting. Certainly, one of them is going to be access. So, there’s a lot being done to improve access to minorities. There’s a whole demographic out there about multiple myeloma in African Americans, and when you slice through all of the data, perhaps the biggest barrier to good outcomes is access to clinical care. So, within the myeloma community, there’s a large effort to see if we can erase that and make things readily available to everyone.
What biomarkers guide treatment protocol in multiple myeloma?
With multiple myeloma, we’re actually in a unique era. Before we used to just stage patients and sort of determine treatment based on stage. Now, it’s considerably more complicated with that, and we’re starting and continuing to do risk stratification, and there’s a lot of debate about who is high risk and who is not. And then I think in this day and age, we’re very fortunate in that we have a lot of agents to pick from and we have a lot of frail elderly multiple myeloma patients where you can now sort of design a very nice regimen that will be effective and well tolerated. So, I think the barriers are really the racial minority barrier and then also finding stuff that we can treat elderly and frail patients with because myeloma is still a disease of the elderly.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More